Drug Trial Radar · NCT05777993
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
55
Planned (sponsor's estimate)
Start
Jul 6, 2023
Primary completion
Aug 2029
Study completion Aug 2031
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to provide continued access to participants who are deriving clinical benefit from ongoing mitapivat treatment in an Agios-sponsored mitapivat study, in the opinion of the Investigator.
Conditions
- Pyruvate Kinase Deficiency
- Anemia, Hemolytic
- Sickle Cell Disease
- Thalassemia
Interventions
MitapivatDrug
Tablets, granules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Not applicable as this protocol is to provide an option for continued access to mitapivat for participants who have previously participated in an Agios-sponsored mitapivat studyTime frame: Not Applicable - Study Completion
Locations
23 sites in 8 countries. Site status is shown where the registry gives one.
Hôpital Erasme
Anderlecht, Brussels Capital, Belgium
HEMORIO Instituto Nacional de Hematologia
Rio de Janeiro, Brazil
Praxis Pesquisa Medica
Santo André, Brazil
GSH Banco de Sangue de São Paulo
São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidad de São Paulo
São Paulo, Brazil
Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
São Paulo, Brazil
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas da Unicamp
Campinas, São Paulo, Brazil
McMaster Centre for Transfusion Medicine McMaster University
Hamilton, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
CHU de Bordeaux - Hôpital Pellegrin
Bordeau, France
CHU Hôpital Henri Mondor
Créteil, France
Hopital Edouard Herriot, CHU de Lyon
Lyon, France
AP-HP - Hôpital Européen Georges Pompidou
Paris, France
Hôpital Necker Enfants Malades
Paris, France
Hopitaux de La Timone
Marseille, Bouches-du-Rhône, France
Rambam Medical Center
Haifa, Ḥeifā, Israel
Ziv Medical Center
Safed, Ḥeifā, Israel
Kyoto Katsura Hospital
Kyoto, Japan
Toho University - Omori Medical Center
Ōta-ku, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Acibadem Adana Hospital
Seyhan, Adana, Turkey (Türkiye)
Manchester Royal Infirmary, Manchester University NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.